The HUREL product portfolio of highly relevant and well-validated 2D co-culture primary hepatocyte models has been acquired by Visikol. Visikol will continue to sell the HUREL product line as well as offer the HUREL portfolio of services. Through this acquisition, Visikol now has the widest portfolio of liver cell culture assays in the marketplace and is able to meet a diverse set of cost, throughput and in vivo relevancy requirements for assessing disease amelioration (e.g., NASH, NAFLD), toxicity and metabolism.
The HUREL portfolio of primary hepatocyte liver models includes ten different species in a flexible 6-384-well format that are delivered directly to researchers for immediate use in their assays.
